Parkinson's disease (PD) is a progressive neurological disorder that primarily affects movement. It is characterized by the degeneration of dopamine-producing neurons in the substantia nigra, a part of the brain that controls movement. This article provides a comprehensive overview of PD, its pathophysiology, clinical manifestations, diagnosis, and treatment options.
The primary pathological feature of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in striatal dopamine levels. This results in an imbalance between the excitatory and inhibitory pathways in the basal ganglia, causing the characteristic motor symptoms of PD. The presence of Lewy bodies, abnormal aggregates of the protein alpha-synuclein, is another hallmark of PD.
PD typically presents with motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. Non-motor symptoms can include autonomic dysfunction, cognitive impairment, mood disorders, and sleep disturbances. The disease progression varies among individuals, with some experiencing rapid progression while others remain stable for several years.
Diagnosis of PD is primarily clinical, based on the presence of characteristic motor symptoms and response to dopaminergic medication. Neuroimaging can be used to support the diagnosis but is not definitive. Treatment is symptomatic, with levodopa being the most effective medication. Other treatment options include dopamine agonists, MAO-B inhibitors, and deep brain stimulation for advanced cases.
Understanding the pathophysiology, clinical manifestations, and treatment options for Parkinson's disease is crucial for healthcare professionals. Despite the progress made in managing PD, there is still no cure, and the disease continues to pose significant challenges. Continued research and development in this field are necessary to improve the quality of life for individuals living with PD.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation